Global Payments Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Global Payments Inc trades at $84.9 (market cap $22.72B), while Vertex Pharmaceuticals Incorporated trades at $529.39 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.9× Global Payments Inc's market cap, and Global Payments Inc pays a 1.16% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| GPN | VRTX | |
|---|---|---|
Market Cap | $22.72B | $134.25B |
Sector | Industrials | Health |
52-Week High | $90.01 | $529.65 |
52-Week Low | $62.47 | $376.62 |
Enterprise Value | $40.87B | $128.37B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $86.13, up slightly by 0.01% today, with a bullish technical signal from moving averages and strong quarterly EPS beats. The company reported Q2 2026 EPS of $3.46, exceeding expectations, but faces headwinds with a negative net income margin of -9.15% in 2026. Recent news highlights Genius platform momentum driving earnings growth, though full-year revenue guidance was trimmed due to Middle East challenges.
Outlook remains cautiously optimistic with a consensus price target of $96.67, offering 12% upside, supported by analyst buy ratings at 58.7%. Key risks include margin pressure from rising costs and intense fintech competition, while institutional interest persists with recent investments like Delta Global Management's $1.74 million stake in Q1 2026.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Trailing returns across standard periods
Latest headlines on both assets
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →